Skip to main content

and
  1. Article

    Open Access

    Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

    Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the...

    Helen E. White, Matthew Salmon, Francesco Albano, Christina Søs Auður Andersen in Leukemia (2022)

  2. Article

    Open Access

    Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

    Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for ...

    Matthew Salmon, Helen E. White, Hana Zizkova, Andrea Gottschalk, Eliska Motlova in Leukemia (2022)

  3. Article

    Open Access

    The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer

    In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the t...

    Silvia R. Vitale, Kirsten Ruigrok-Ritstier, A. Mieke Timmermans in BMC Cancer (2022)

  4. Article

    Open Access

    Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer

    Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect circulating tumor-derived EVs (ctEV...

    Silvia R. Vitale, Jean A. Helmijr, Marjolein Gerritsen, Hicret Coban in BMC Cancer (2021)

  5. Article

    Open Access

    Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

    BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...

    Simona Soverini, Elisabetta Abruzzese, Monica Bocchia in Journal of Hematology & Oncology (2019)

  6. Article

    Open Access

    Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

    The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic ...

    Michele Massimino, Stefania Stella, Elena Tirrò, Chiara Romano in Molecular Cancer (2018)

  7. Article

    Open Access

    IRF5 promotes the proliferation of human thyroid cancer cells

    Interferon Regulatory Factor 5 is a transcription factor that regulates the expression of genes involved in the response to viral infection and in the stimulation of the immune system. Moreover, multiple studi...

    Michele Massimino, Paolo Vigneri, Manuela Fallica, Annamaria Fidilio in Molecular Cancer (2012)

  8. No Access

    Article

    Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase

    The chimeric BCR–ABL oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). BCR–ABL contains nuclear import and export signals but it is localized only in the cytoplasm where it activates...

    Paolo Vigneri, Jean Y. J. Wang in Nature Medicine (2001)